ImPact Biotech Presents Phase 3 ENLIGHTED Study Interim Data on Padeliporfin VTP for Low Grade UTUC at Medical Conferences

ImPact Biotech, a company in the phase of clinical trials, is dedicated to the advancement of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP), a treatment for various solid tumors. They have recently announced that their abstracts have been accepted for presentation at significant medical conferences, which include early findings from the ENLIGHTED Phase 3 study involving Padeliporfin VTP treatment for patients with low-grade upper tract urothelial cancer (UTUC).

The company's Chief Medical Officer, Eyal Morag, expressed enthusiasm for the preliminary data from the ENLIGHTED study, which is set to be presented at both AUA and ASCO. He highlighted the promising results from their Phase 1 study, which showed a strong effect and a favorable safety profile. ImPact Biotech is striving to establish the superiority of Padeliporfin VTP over the existing standard of care for UTUC. Additionally, the company is broadening the application of its platform to treat other solid tumors, with a particular focus on pancreatic cancer (PDAC), a notoriously difficult cancer to treat. The aim is to transform patients with locally advanced, unresectable PDAC into candidates eligible for surgery, thus expanding the pool of individuals who can be treated. Clinical sites for a Phase 1 study in this area have been initiated, with patient dosing expected to commence in the near future.

At the American Urology Association's Annual Meeting in May, ImPact Biotech will present preliminary data from the ongoing ENLIGHTED study. The presentation will be led by Prof. Ronald Kaufman and will focus on the efficacy and safety of Padeliporfin VTP in treating low-grade UTUC.

Furthermore, two abstracts have been selected for poster presentation at the American Society of Clinical Oncology Annual Meeting in June. These will provide additional data from the Phase 3 ENLIGHTED study and showcase the design of the upcoming Phase 1 study of Padeliporfin VTP in PDAC. The authors of these abstracts include a range of experts in the field, indicating a collaborative effort in advancing cancer treatment.

ImPact Biotech's VTP therapy is a minimally invasive drug-device combination designed to selectively eliminate inoperable solid tumors. The innovative platform uses optical fibers to deliver laser light locally, activating Padeliporfin within the tumor environment. The therapy is currently under evaluation in a pivotal Phase 3 study for low-grade UTUC, with further studies planned or underway for high-grade UTUC, PDAC, and non-small cell lung cancer (NSCLC). The company collaborates with esteemed institutions such as the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operates across the EU, Israel, and the US.